Loading company
Rezolute, Inc.
RZLT · Nasdaq · ·
Next earnings: November 5, 2026
$4.09-1.7%Sep 29 close
- 1M
- -11.5%
- 6M
- +43.5%
- 1Y
- -56.5%
- 5Y
- -49.2%
RZLT · Nasdaq · ·
Next earnings: November 5, 2026
$4.09-1.7%Sep 29 close
Rezolute, Inc. is scheduled to report next on November 5, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toJun 30, 2025 | Change |
|---|---|---|---|
| Profit | -$20.5M | -$24.4M | +15.99% |
| Profit per share | -$0.20 | -$0.26 | +23.08% |
| Free Cash Flow | -$11.4M | -$4.1M | -178.32% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Rezolute, Inc. has no earnings call transcript available.
Releases land after the close or before the open, so the move is the session that follows.
Ersodetug is a fully human monoclonal antibody that binds allosterically to the insulin receptor to decrease receptor over-activation by insulin and related substances (such as IGF-2) in the setting of hyperinsulinism (HI), thereby improving hypoglycemia. Because ersodetug acts downstream from pancreatic insulin or paraneoplastic IGF-2 secretion and from entero-incretin pathways, it has the potential to be universally effective at treating refractory hypoglycemia due to any form of hyperinsulinism (HI), including congenital HI, tumor HI (insulinoma, non-islet cell tumors) or bariatric/non-bariatric gastrointestinal surgery hypoglycemia. Ersodetug for the treatment of HI is investigational. Statements about safety and efficacy have not been approved by any health authority.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Rezolute, Inc.’s Item 2.02 8-K filed September 24, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.